# US 2014/0193908 A1 · Sequential antibody therapy

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2014/0193908 A1
- Document ID: US20140193908A1
- Status: Published application
- Kind: A1
- Application number: 14/233,456
- Filed: 2012-06-22
- Published: 2014-07-10
- Earliest claimed: 2011-07-19
- Assignees: Philogen S.P.A.
- Inventors: Kathrin Schwager
- Web page: https://patentgrep.com/patent/US20140193908A1

## CPC

- A61K 39/39558: {against tumor tissues, cells, antigens}
- A61K 38/2013: {IL-2}
- A61K 39/39541: {against normal tissues, cells}
- A61P 35/00: Antineoplastic agents
- C07K 16/18: against material from animals or humans
- C07K 16/2818: {against CD28 or CD152}
- C12N 5/0693: {Tumour cells; Cancer cells}
- C07K 2319/33: fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The invention provides a blocking ligand specific for CTLA-4 and a vascular targeting ligand/IL-2 complex, for sequential use in inhibiting the growth of tumour cell

## Claims

### Claim 1

A method for inhibiting the growth of a tumour cell comprising contacting said cell with a ligand specific for CTLA-4 and a vascular targeting ligand/IL-2 complex.

### Claim 2 (depends on 1)

A method according to claim 1, wherein the ligand specific for CTLA-4 is selected from an antibody, a peptide and a nucleic acid aptamer specific for CTLA-4.

### Claim 3 (depends on 2)

A method according to claim 2, wherein the ligand specific for CTLA-4 is a nucleic acid aptamer specific for CTLA-4.

### Claim 4 (depends on 3)

A method according to claim 3, wherein the mutant aptamer is an RNA aptamer.

### Claim 5 (depends on 2)

A method according to claim 2, wherein the ligand specific for CTLA-4 is an anti-CTLA-4 antibody.

### Claim 6 (depends on 5)

A method according to claim 5, wherein the antibody is a scFv.

### Claim 7 (depends on 1)

A method according to claim 1, wherein the vascular targeting ligand is selected from an antibody and a peptide specific for a vascular marker.

### Claim 8 (depends on 7)

A method according to claim 7, wherein the vascular targeting ligand is an antibody.

### Claim 9 (depends on 8)

A method according to claim 8, wherein the vascular targeting ligand is specific for the alternatively spliced extradomain B of fibronectin, domain A1 of tenascin C, or extradomain A of fibronectin.

### Claim 10 (depends on 1)

A method according to claim 1, wherein the ligand specific for CTLA-4 is administered before the vascular targeting ligand/IL-2 complex.

### Claim 11 (depends on 10)

A method according to claim 10, wherein the tumour cells are part of a solid tumour, and treatment results in reduction in tumour size.

### Claim 12 (depends on 11)

A method according to claim 11, wherein the ligand specific for CTLA-4 is administered one day before the vascular targeting ligand/IL-2 complex.

### Claim 13 (depends on 10)

A method according to claim 10, wherein the administration of both the ligand specific for CTLA-4 and the vascular targeting ligand/IL-2 complex is repeated.

### Claim 14 (depends on 13)

A method according to claim 13, wherein the repeat administrations occur four days apart.

### Claim 15

(canceled)

### Claim 16 (depends on 1)

A method according to claim 1, wherein contacting said cell with a ligand specific for CTLA-4 and a vascular targeting ligand/IL-2 complex is performed sequentially.